🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

42 results for “Chinese University of Hong Kong” Clear

  1. Finerenone

    Chinese University of Hong Kong

    Patients With Type 2 Diabetes

    approved small molecule active

    1 trial

  2. Pegyinterferon-alfa-2a

    Chinese University of Hong Kong

    Chronic Hepaititis B

    approved small molecule completed

    1 trial

  3. Sodium valproate

    Chinese University of Hong Kong

    Epilepsy

    approved small molecule active

    1 trial

  4. film dressing by adhesive

    Chinese University of Hong Kong

    Chronic Peritoneal Dialysis

    approved other terminated

    1 trial

  5. inactivated EV71 vaccine (KMB-17 cells)

    Chinese University of Hong Kong

    Hand, Foot and Mouth Disease (HFMD)

    approved mab completed

    1 trial

  6. lactate group:lactate acide clearance directed group; ScvO2 group:ScvO2 directed group;control group

    Chinese University of Hong Kong

    Shock, Septic

    approved other completed

    1 trial

  7. tacrolimus

    Chinese University of Hong Kong

    Lupus Nephritis

    approved small molecule completed

    1 trial

  8. Clarithromycin

    Chinese University of Hong Kong

    Bronchiectasis Adult

    small molecule active

    1 trial

  9. Computer Aided Diagnosis

    Chinese University of Hong Kong

    Upper Gastrointestinal Disorder

    other completed

    1 trial

  10. Du-Huo-Ji-Sheng-Tang (DHJST)

    Chinese University of Hong Kong

    Knee Osteoarthritis

    small molecule active

    1 trial

  11. EUS-guided portal vein and hepatic vein aspiration

    Chinese University of Hong Kong

    Circulating Tumor Cell

    other active

    1 trial

  12. Intensive BP control

    Chinese University of Hong Kong

    Primary Hypertension

    small molecule active

    1 trial

  13. Mesalazine

    Chinese University of Hong Kong

    Colitis, Ulcerative

    small molecule completed

    1 trial

  14. Methotrexate

    Chinese University of Hong Kong

    Rheumatoid Arthritis

    small molecule completed

    1 trial

  15. Physiotherapy

    Chinese University of Hong Kong

    Knee Arthropathy

    other active

    1 trial

  16. Telbivudine

    Chinese University of Hong Kong

    Chronic Hepatitis B

    small molecule terminated

    1 trial

  17. Western therapy

    Chinese University of Hong Kong

    Hand, Foot and Mouth Disease

    small molecule completed

    1 trial

  18. β-hydroxy β-methylbutyrate (HMB) supplement

    Chinese University of Hong Kong

    Sarcopenia

    other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources